Collegium Pharmaceutical, Inc. COLL Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Product revenues, net by Product | |||||
| Belbuca | $221.65M+4.9% | $211.27M+16.0% | $182.1M+44.0% | $126.46M— | |
| Jornay PM | $148.86M— | —— | $0— | —— | |
| Nucynta ER | $80.99M+6.9% | $75.77M-8.3% | $82.65M+14.1% | $72.42M+2.1% | |
| Nucynta IR | $115.31M+14.5% | $100.74M-6.9% | $108.15M-3.5% | $112.06M+9.6% | |
| Symproic and other | $14.45M-4.3% | $15.1M-8.4% | $16.5M— | —— | |
| Finite-Lived Intangible Assets, Net by Product | |||||
| Belbuca | $414.66M-42.1% | $716.23M-29.6% | $1.02B-23.4% | $1.33B— | |
| Jornay PM | $2.22B— | —— | —— | —— | |
| Symproic | $180.92M-13.9% | $210.05M-12.2% | $239.2M-10.9% | $268.35M— | |
| Cost, Amortization by Product | |||||
| Belbuca | $75.4M0.0% | $75.39M0.0% | $75.39M— | —— | |
| Jornay PM | $83.83M— | —— | $0— | —— | |
| Finite-Lived Intangible Asset, Expected Amortization, Year Four by Product | |||||
| Jornay PM | $335.32M— | —— | —— | —— | |
| Cost by Product | |||||
| Belbuca | $1.44B0.0% | $1.44B0.0% | $1.44B-0.7% | $1.45B— | |
| Jornay PM | $2.54B— | —— | —— | —— | |
| Symproic | $280M0.0% | $280M0.0% | $280M0.0% | $280M— | |
| Finite-Lived Intangible Assets, Accumulated Amortization by Product | |||||
| Belbuca | $1.03B+41.7% | $723.77M+71.4% | $422.19M+250% | $120.68M— | |
| Jornay PM | $318.54M— | —— | —— | —— | |
| Symproic | $99.08M+41.6% | $69.95M+71.5% | $40.8M+250% | $11.66M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Collegium Pharmaceutical, Inc. break its business down?
- Collegium Pharmaceutical, Inc. (COLL) reports product revenues, net by product across 9 parts — Belbuca, Jornay PM, Nucynta ER AG, Nucynta ER and Nucynta IR AG. Each is extracted from the segment footnotes and tracked over time.
- Where does Collegium Pharmaceutical, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Collegium Pharmaceutical, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
